![We are running out of bullets for dealing with a number of (bacterial) infections. Patients are dying because we no longer in many cases have antibiotics that work. Nobel Laureate Joshua Lederberg](images/mainQuote.gif)
Dr. Michael Dunne and Dr. Paul Miller of Pfizer got into antibiotic development because they wanted to make a difference in the lives of patients. But the obstacle course of scientific, economic, and regulatory barriers has lead to a reduction in investment in new antibiotics, just at a time of growing medical need...
Bacterial infections that cannot be cured by existing antibiotics are becoming more common every day and are exacting a terrible price on patients and healthcare providers in the United States.
A supply of effective and affordable antibiotics cannot be sustained without changes to the real-world incentives facing patients, physicians, hospitals, insurers, and pharmaceutical manufacturers.
Our inaugural report, Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance, is a comprehensive study that explores incentive-based policies to protect antibiotic effectiveness, a valuable shared resource.
Research by ETC’s David L. Smith noted in The New Yorker.
New research on VRE from ETC’s Eili Klein.
ETC comments on recent MRSA research.